AR011706A1 - Formulacion en aerosol de tobramicina para el tratamiento, prevencion y contencion de la tuberculosis - Google Patents

Formulacion en aerosol de tobramicina para el tratamiento, prevencion y contencion de la tuberculosis

Info

Publication number
AR011706A1
AR011706A1 ARP980101499A ARP980101499A AR011706A1 AR 011706 A1 AR011706 A1 AR 011706A1 AR P980101499 A ARP980101499 A AR P980101499A AR P980101499 A ARP980101499 A AR P980101499A AR 011706 A1 AR011706 A1 AR 011706A1
Authority
AR
Argentina
Prior art keywords
tuberculosis
prevention
treatment
containment
tobramycin
Prior art date
Application number
ARP980101499A
Other languages
English (en)
Original Assignee
Pathogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathogenesis Corp filed Critical Pathogenesis Corp
Publication of AR011706A1 publication Critical patent/AR011706A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El tratamiento y prevencion de la tuberculosis pulmonar por vía sistémica ya no es recomendable por el hecho que las concentraciones necesarias en sangreson muy proximas a aquéllas que pueden provocar acciones toxicas. Ello se ha traducido a quehoy se recurra a formulaciones, fundamentalmente a base deantibioticos, de accion local. No obstante, dado que las secreciones bronquiales son de difícil penetracion, aparte de actuar como inhibidoras de laactividad propia de aquellas drogas, los resultados no han sido los esperados. Mediante esta invencion se provee una formulacion a base de una altaconcentracion, comprendida entre 1.000 y 10.000 veces la concentracion inhibitoria mínima de la bacteria Mycobactrium tuberculosis, de tobramicina,en un pequeno volumen de solucion salina con un pH comprendido entre 5,0 y 7,5 que, aplicada, en aerosol en partículas cuyo tamano oscila entre 1 y 5 micronesaproximadamente, resulta altamente eficaz para la inhibicion y destruccion de tal bacteria.
ARP980101499A 1997-04-02 1998-04-02 Formulacion en aerosol de tobramicina para el tratamiento, prevencion y contencion de la tuberculosis AR011706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/825,725 US6083922A (en) 1996-04-02 1997-04-02 Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis

Publications (1)

Publication Number Publication Date
AR011706A1 true AR011706A1 (es) 2000-08-30

Family

ID=25244769

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101499A AR011706A1 (es) 1997-04-02 1998-04-02 Formulacion en aerosol de tobramicina para el tratamiento, prevencion y contencion de la tuberculosis

Country Status (7)

Country Link
US (1) US6083922A (es)
AR (1) AR011706A1 (es)
AU (1) AU6469198A (es)
BR (1) BR9801008A (es)
IL (1) IL123848A (es)
WO (1) WO1998043650A1 (es)
ZA (1) ZA982447B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU2002247280A1 (en) * 2001-03-09 2002-09-24 Antares Pharma, Inc. Ocular drug delivery nebulizer
AU2007202942B2 (en) * 2001-05-18 2010-05-27 Novartis Ag Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
EP1598059A1 (en) * 2001-05-18 2005-11-23 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
EP2186508A3 (en) * 2001-05-18 2010-08-25 Novartis AG Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
WO2003037365A1 (en) * 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
WO2003092654A1 (en) 2002-05-02 2003-11-13 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
US20050220720A1 (en) * 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
US7334580B2 (en) * 2002-05-07 2008-02-26 Smaldone Gerald C Methods, devices and formulations for targeted endobronchial therapy
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
ATE501766T1 (de) 2003-05-20 2011-04-15 James F Collins Ophthalmisches arzneimittelabgabesystem
US8012136B2 (en) 2003-05-20 2011-09-06 Optimyst Systems, Inc. Ophthalmic fluid delivery device and method of operation
ATE350024T1 (de) * 2003-10-15 2007-01-15 Pari Gmbh Flüssige zubereitung enthaltend tobramycin
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
PT2316419E (pt) 2004-05-17 2012-10-22 Gilead Sciences Inc Combinação de fosfomicina/aminoglicósido em aerossol para o tratamento de infeções respiratórias bacterianas
US8627821B2 (en) * 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
AU2006244478B2 (en) * 2005-05-05 2012-09-13 Pulmatrix Inc. Ultrasonic aerosol generator
CA2900093C (en) 2005-05-18 2018-11-13 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
EA016072B1 (ru) * 2005-05-18 2012-01-30 Палметрикс Инк. Применение состава соли кальция для изменения биофизических свойств слизистой оболочки
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
AU2006297289B2 (en) * 2005-09-29 2013-03-21 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
US20100137239A1 (en) 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
KR20090077914A (ko) 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 항증식제로서의 다작용성 소분자
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
WO2010042549A1 (en) 2008-10-07 2010-04-15 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
NZ592717A (en) 2008-10-07 2013-03-28 Mpex Pharmaceuticals Inc Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
MX2011008982A (es) 2009-02-27 2011-09-15 Enata Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.
HRP20171415T4 (hr) 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
US20110014273A1 (en) * 2009-07-15 2011-01-20 Helmut Brunar Method of Treating BCC
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
JP6076740B2 (ja) 2010-01-07 2017-02-08 アルカーメス ファーマ アイルランド リミテッド 第四級アンモニウム塩プロドラッグ
EP2585066B1 (en) 2010-06-24 2018-09-26 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
WO2012009702A1 (en) 2010-07-15 2012-01-19 Corinthian Ophthalmic, Inc. Method and system for performing remote treatment and monitoring
WO2012009696A2 (en) 2010-07-15 2012-01-19 Corinthian Ophthalmic, Inc. Ophthalmic drug delivery
CA2805426C (en) 2010-07-15 2020-03-24 Corinthian Ophthalmic, Inc. Drop generating device
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
ES2899621T3 (es) 2010-09-29 2022-03-14 Pulmatrix Operating Co Inc Polvos secos catiónicos que comprenden sal de magnesio
IL286573B (en) 2010-09-29 2022-08-01 Pulmatrix Operating Co Inc Monovalent metallic cation dry powders for inhalation
AU2011348085B2 (en) 2010-12-23 2016-12-08 Alkermes Pharma Ireland Limited Multi- API loading prodrugs
TWI574687B (zh) 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
DK2670242T3 (da) 2011-01-31 2022-05-02 Avalyn Pharma Inc Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf
ES2733128T3 (es) 2011-04-01 2019-11-27 Curis Inc Inhibidor de fosfoinosítido 3-quinasa con un resto de unión a cinc
WO2013090468A1 (en) 2011-12-12 2013-06-20 Corinthian Ophthalmic, Inc. High modulus polymeric ejector mechanism, ejector device, and methods of use
WO2013088242A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with opioid agonists
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
WO2013130767A1 (en) 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
JP6501264B2 (ja) 2012-07-24 2019-04-17 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
WO2014160478A1 (en) 2013-03-13 2014-10-02 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
EP3027026A4 (en) 2013-07-31 2017-05-03 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
CN106459993A (zh) 2014-03-31 2017-02-22 德彪药业国际股份公司 Fgfr融合体
EP3185898B1 (en) 2014-08-26 2022-04-06 HSF Pharmaceuticals Novel immunization agents and methods of use
CN107106546A (zh) 2014-10-06 2017-08-29 弗拉特利发现实验室有限责任公司 三唑并吡啶化合物和用于治疗囊性纤维化的方法
CA3017020C (en) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
EP3512602B1 (en) 2016-09-16 2024-03-27 HSF Pharmaceuticals Inhibitors of heat shock factors (hsf) and uses thereof
CN111093742B (zh) 2017-06-10 2022-09-16 艾诺维亚股份有限公司 用于处理流体并将流体输送到眼睛的方法和设备
WO2019110099A1 (en) 2017-12-06 2019-06-13 Qrumpharma Inc. Inhalable clofazimine formulation
EP3762024A1 (en) 2018-03-08 2021-01-13 HSF Pharmaceuticals Localized activation of virus replication boosts herpesvirus-vectored vaccines
US20210128735A1 (en) 2018-05-10 2021-05-06 Cis Pharma Ag Biocompatible copolymer containing multiple active agent molecules
KR20210090607A (ko) 2018-08-23 2021-07-20 맨카인드 코포레이션 클로파지민의 조성물, 이들을 포함하는 조합물, 이들의 제조 방법, 이들을 포함하는 용도 및 방법
BR112021005091A2 (pt) 2018-09-21 2021-06-08 Enanta Pharmaceuticals, Inc. heterociclos funcionalizados como agentes antivirais
EP3653716A1 (en) 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
BR112021023832A8 (pt) 2019-06-04 2023-02-28 Thirty Holdings Ltd Métodos e composições para geração de óxido nítrico e usos dos mesmos
JP2023510662A (ja) 2019-06-04 2023-03-15 サーティー レスピラトリー リミテッド 窒素酸化物を生成するための方法および組成物、ならびに気道を介して窒素酸化物を送達するためのそれらの使用
CA3150503A1 (en) 2019-10-30 2021-05-06 Cis Pharma Ag BIOCOMPATIBLE POLYMERIC MEDICATION CARRIES FOR THE DELIVERY OF ACTIVE AGENTS
CN115884758A (zh) 2020-04-23 2023-03-31 三十呼吸有限公司 用于治疗SARS-CoV和SARS-CoV-2的一氧化氮或释放一氧化氮的组合物
WO2021214439A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Methods and compositions for treating and combatting tuberculosis
EP4138898A1 (en) 2020-04-24 2023-03-01 HSF Pharmaceuticals Replication-competent controlled herpesviruses expressing a sars cov-2 antigen
KR20230054611A (ko) 2020-06-01 2023-04-25 애드벤트 테라퓨틱스 인크. 불용성 활성 성분을 포함하는 약제학적 조성물
US20230233514A1 (en) 2020-06-23 2023-07-27 Flagship Pioneering, Inc. Antiviral compounds and methods of using the same
MX2023000798A (es) 2020-07-20 2023-02-27 Enanta Pharm Inc Peptidos funcionalizados como agentes antivirales.
CN114524821A (zh) 2020-11-23 2022-05-24 英安塔制药有限公司 新型螺旋吡咯烷衍生的抗病毒药物
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2023006993A1 (en) 2021-07-30 2023-02-02 Atmosr Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization

Also Published As

Publication number Publication date
IL123848A0 (en) 1998-10-30
IL123848A (en) 2002-12-01
US6083922A (en) 2000-07-04
AU6469198A (en) 1998-10-22
ZA982447B (en) 1999-01-26
WO1998043650A1 (en) 1998-10-08
BR9801008A (pt) 2001-03-20

Similar Documents

Publication Publication Date Title
AR011706A1 (es) Formulacion en aerosol de tobramicina para el tratamiento, prevencion y contencion de la tuberculosis
CO4940408A1 (es) Composicion de aerosol farmaceutico
ES2104922T3 (es) Composiciones basadas en acidos grasos para combatir infecciones declaradas en plantas.
DK0918507T3 (da) Aerosolformuleringer
GT199900197A (es) Formulaciones antiparasitarias.
ES2194501T3 (es) Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
AR019772A1 (es) Composiciones antimicrobianas en aerosol
DE59909615D1 (de) Mittel zur abwehr und inaktivierung pathogener erreger von pflanzen
CO4230155A1 (es) Agentes sinergicos para combatir insectos y acaros .
DE69501419T2 (de) Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose enthaltend Xanthohumol
ES2181017T3 (es) Composicion farmaceutica que contiene una sustancia promotora de osteogenesis y un polietilenglicol.
BR9814299A (pt) Aminobiguanidas e o seu uso para desinfetarlentes de contato e preservar composiçõesfarmacêuticas
HUP0104410A2 (hu) Ateroszklerózis megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmények
FI813857L (fi) Abrasivt verkande medel och deras anvaendning
AR038333A1 (es) Desinfectante/esterilizante de baja temperatura para dipositivos medicos y aplicaciones topicas
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
CO5261494A1 (es) Composiciones farmaceuticas acuosas e hipotonicas de ciclesonida que presentan absorcion nasal mejorada
PT1251737E (pt) Composicoes tratadas para inactivar proteinas infecciosas
ES2041243T3 (es) Aplicacion de por lo menos un principio activo inhibidor o destructor de por lo menos un ser vivo unicelular o virus.
ES2191083T3 (es) Composicion para limpiar y/o desinfectar instrumentos para uso medico.
ES2177324T3 (es) Preparaciones de insulina destinadas a la entrega pulmonar y que contiene mentol.
ES2130102T1 (es) Composicion cosmetica adelgazante que contiene un extracto de chrysanthellum indicum.
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen

Legal Events

Date Code Title Description
FC Refusal